Volume 47 Issue 2, February 2026
Cover story: Compared with traditional ADC T-Dxd, Wang et al. report novel anti-HER2 nanobody-drug conjugates (HER2-NDCs) with enhanced tumor distribution, increased BBB permeability, reduced systemic exposure, and improved tumor inhibition and antitumor immune response. This highly differentiated PK/PD profile will benefit treatment outcome. Doi: 10.1038/s41401-025-01634-3.
